This Article Full Text Full Text (PDF) All Versions of this Article: 34/4/1038    most recent 01.STR.0000063139.06585.45v1 Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Permissions Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Montaner, J. Articles by Alvarez-Sabín, J. Search for Related Content PubMed PubMed Citation Articles by Montaner, J. Articles by Alvarez-Sabín, J. Related Collections Arterial thrombosis Thrombin Acute Stroke Syndromes Coagulation and fibronolysis

(Stroke. 2003;34:1038.)
© 2003 American Heart Association, Inc.

Research Reports

Thrombin-Activable Fibrinolysis Inhibitor Levels in the Acute Phase of Ischemic Stroke

Joan Montaner, MD, PhD; Marc Ribó, MD; Jasone Monasterio, MD, PhD; Carlos A. Molina, MD, PhD José Alvarez-Sabín, MD, PhD

From the Cerebrovascular Unit (J. Montaner, M.R, C.A.M, J.A.S) and the Vascular Biology and Hemostasia Unit (J. Montaner, J. Monasterio), Vall d’Hebron Hospital, Barcelona, Spain.

Correspondence to Dr Joan Montaner, Unidad Cerebrovascular, Servicio de Neurología, 6^a Planta, Hospital General, Hospital Vall d’Hebron, Pg Vall d’Hebron 119-129, 08035 Barcelona, Spain. E-mail 31862jmv{at}comb.es

Abstract

Background and Purpose— Thrombin-activable fibrinolysis inhibitor (TAFI) is a recently identified fibrinolysis inhibitor in plasma. The purpose of this work was to study TAFI levels in the acute phase of ischemic stroke and their relationship with stroke evolution.

Methods— In 30 consecutive ischemic stroke patients, TAFI plasma levels were measured by means of enzyme-linked immunosorbent assay (percentage of the pooled reference kit expressed as mean±SD) and compared with the values obtained in 30 healthy control subjects. All samples were drawn within the first 24 hours after symptom onset (mean, 4.6 hours) and before any treatment was started.

Results— TAFI plasma concentration was significantly higher (P<0.001) in stroke patients (158.4±53.2%) than in healthy control subjects (105.6±30.2%). The highest TAFI levels were found in cases of neurological deterioration (worsening, 198.1±63.0%; stability, 130.5±39.3%; improvement, 173.9±52.0%; P=0.057).

Conclusions— High levels of TAFI are found in the acute phase of ischemic stroke.

Key Words: carboxypeptidase U • cerebral ischemia • stroke • TAFI • thrombolysis

This article has been cited by other articles:

				C. Ladenvall, A. Gils, K. Jood, C. Blomstrand, P. J. Declerck, and C. Jern Thrombin Activatable Fibrinolysis Inhibitor Activation Peptide Shows Association With All Major Subtypes of Ischemic Stroke and With TAFI Gene Variation Arterioscler. Thromb. Vasc. Biol., April 1, 2007; 27(4): 955 - 962. [Abstract] [Full Text] [PDF]

				I. B. Kovacs and J. Yamamoto Spontaneous thrombolysis: a forgotten determinant of life or death. Clinical and Applied Thrombosis/Hemostasis, July 1, 2006; 12(3): 358 - 363. [Abstract] [PDF]

				E. Ceresa, E. Brouwers, M. Peeters, C. Jern, P. J. Declerck, and A. Gils Development of ELISAs Measuring the Extent of TAFI Activation Arterioscler. Thromb. Vasc. Biol., February 1, 2006; 26(2): 423 - 428. [Abstract] [Full Text] [PDF]

				R. Renckens, J. J. T. H. Roelofs, S. A. J. ter Horst, C. van 't Veer, S. R. Havik, S. Florquin, G. T. M. Wagenaar, J. C. M. Meijers, and T. van der Poll Absence of Thrombin-Activatable Fibrinolysis Inhibitor Protects against Sepsis-Induced Liver Injury in Mice J. Immunol., November 15, 2005; 175(10): 6764 - 6771. [Abstract] [Full Text] [PDF]

				M. Ribo, J. Montaner, C. A. Molina, J. F. Arenillas, E. Santamarina, M. Quintana, and J. Alvarez-Sabin Admission Fibrinolytic Profile Is Associated With Symptomatic Hemorrhagic Transformation in Stroke Patients Treated With Tissue Plasminogen Activator Stroke, September 1, 2004; 35(9): 2123 - 2127. [Abstract] [Full Text] [PDF]

				K. Suzuki, Y. Muto, K. Fushihara, K.-i. Kanemoto, H. Iida, E. Sato, C. Kikuchi, T. Matsushima, E. Kato, M. Nomoto, et al. J. Pharmacol. Exp. Ther., May 1, 2004; 309(2): 607 - 615. [Abstract] [Full Text] [PDF]